Clinical trials: Acute Hematogenous Osteomyelitis
Acute Hematogenous Osteomyelitis
Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)
The purpose of the study is to determine whether daptomycin is effective and safe in the treatment of pediatric participants with AHO when compared to vancomycin (or equivalent) or nafcillin (or β-lactam equivalent).
- Trial name
- NCT01922011
- Testing
- Daptomycin, Vancomycin (or equivalent), Nafcillin (or equivalent)
- Volunteers
- 149 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)